Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (Becton, Dickinson and Company) celebrates 25 years of partnership with Mercy Ships, announcing a donation of $1 million to support the launch of the Global Mercy, the world's largest NGO hospital ship. This contribution increases BD's total philanthropic investment in Mercy Ships to $2.5 million. The ship, set to sail to Africa in late 2021, features advanced medical facilities and aims to address the severe lack of surgical care, particularly in Africa, where 93% of the 18.6 million annual deaths due to inadequate surgical access occur.
BD (Becton, Dickinson and Company) has received 510(k) clearance from the U.S. FDA for its FACSLyric™ Flow Cytometer combined with the BD FACSDuet™ Sample Preparation System. This integrated system fully automates the sample-to-answer process, enhancing laboratory efficiency by reducing errors and minimizing manual interventions. The FACSDuet provides a walkaway solution that streamlines workflows and improves data integration with laboratory systems. The system is now available as an IVD system in the U.S. and countries recognizing CE-IVD certification.
BD (Becton, Dickinson and Company) announced a live webcast for its fourth fiscal quarter and full fiscal year 2020 earnings conference call on November 5, 2020, at 8:00 a.m. (ET). The earnings press release will precede the call. Investors can access the webcast and related slides on the company's investor website, with a replay available until November 12, 2020. BD operates globally, focusing on advancing health through innovative medical technologies, enhancing care delivery, and supporting health care providers.
BD (Becton, Dickinson and Company) has announced that its SARS-CoV-2 antigen test for the BD Veritor™ Plus System has received CE marking, allowing for commercial availability in Europe by the end of October. This rapid test provides results in just 15 minutes, enhancing COVID-19 diagnostic turnaround times. BD plans to produce 8 million tests per month by October and 12 million by March 2021. The system, already in use for other respiratory conditions, allows simultaneous testing for SARS-CoV-2 and influenza A+B, addressing critical healthcare needs during flu season.
On September 23, 2020, BD (Becton, Dickinson and Company) submitted a PMA supplement to the FDA for the ThinPrep® Pap Test™ PreservCyt® Solution vial as an approved sample type for its BD Onclarity™ HPV Assay. This submission aims to expand sample claims beyond the BD SurePath™ vial, providing crucial performance data for BD Viper™ LT and BD COR™ Systems. The company recently received FDA approval for extended genotype reporting, enhancing the assay's capabilities. This commitment underscores BD's focus on improving cervical cancer screening and patient management.
BD (Becton, Dickinson and Company) has updated the status of its voluntary recalls of the BD Alaris™ System, initiated on August 4, 2020. The FDA classified three recalls as Class I, indicating a significant risk of serious health consequences or death, while one was classified as Class II. The recalls address issues such as unresponsive keypad keys and incorrect module sizes for infusion pumps, potentially leading to delays or inaccuracies in medication delivery. Customers are advised to follow recall instructions provided by BD.
BD (Becton, Dickinson and Company) announced a study showing the BD Veritor™ System for Rapid Detection of SARS-CoV-2 is as effective as the Quidel Sofia 2 SARS Antigen Fluorescent Immunoassay. The research involved 361 patient samples, indicating a high agreement in testing accuracy. The BD Veritor™ Plus system showed better correlation with PCR results than its competitor. The study aims to assess performance in community settings and highlights the importance of various factors in understanding antigen assay performance. The findings support the rapid antigen tests' utility in managing COVID-19.
BD (Becton, Dickinson and Company) (NYSE:BDX) announced its participation in upcoming virtual investor healthcare conferences. The company will present at the Wells Fargo Securities 2020 Healthcare Conference on September 10, 2020, at 8:40 a.m. EDT, and the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 8:45 a.m. EDT. Webcasts of these presentations will be available on their corporate website and can be replayed for seven days post-conference.
BD (Becton, Dickinson and Company) has updated its voluntary recall of the BD Alaris™ System due to hardware issues. The U.S. FDA has classified three of the situations as Class I recalls, indicating a high probability of serious health risks or death, while one situation is a Class II recall. The issues include damaged connectors and battery problems that may impact device operation. BD has provided corrective instructions to affected customers, emphasizing the importance of safety in medical technology.
BD (Becton, Dickinson and Company) announced the appointment of Kristen Stewart as the senior vice president of Strategy and Investor Relations, effective Aug. 31, 2020. Stewart brings nearly two decades of experience in the medical technology sector, having previously led research at Barclays Capital. Her role will focus on enhancing shareholder value and communicating BD's long-term growth strategy. Tom Polen, CEO of BD, expressed confidence in her strategic skills, while Christopher Reidy, CFO, noted her strong investment community ties.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
